The US fertility rate continued its decline to historic lows in 2025, driven by two converging trends: teen pregnancy rates have plummeted, and more women are delaying motherhood into their 30s and 40s.

The teen birth rate sat at 11.7 births per 1,000 females aged 15-19 — a number that would have been unimaginable a generation ago when it was around 60. That’s a genuine public health success, attributable to better access to contraception and shifting norms.

Bangladesh has launched an emergency MMR vaccine campaign after health data confirmed at least 130 children dead from measles in the past six weeks. The outbreak signals a collapse in vaccination coverage — measles deaths at this scale in a country with an established health infrastructure indicate that a significant portion of children were not reaching the immune status the MMR vaccine provides.

The causes of such gaps are usually layered: supply chain disruptions, displacement, community resistance, or simply the erosion of routine immunization programs during periods of economic pressure. Bangladesh has dealt with all of these in recent years.

One week of intensive meditation practice: improved brain efficiency, boosted immune signaling, increased natural pain relief chemicals.

Seven days. Not years of practice. The brain responds faster than most people assume.

Whether this persists or fades without continued practice isn’t answered here. But “measurable changes in a week” is a more accessible finding than the usual “long-term meditators show differences.”

Deepfake X-rays are now convincing enough that radiologists in tests couldn’t reliably tell them apart from real ones — especially when they didn’t know fakes were in the mix.

The obvious nightmare scenarios write themselves: insurance fraud, evidence fabrication, diagnostic errors from compromised image databases.

The less obvious one: this probably forces a rethink of how medical images are authenticated and stored. Digital signatures for scans, chain-of-custody verification. It’s all possible, just not standard yet.

Not “every weekend.” Once a month. If you drink heavily once a month and otherwise moderately, you may be tripling your risk of liver fibrosis.

Everyone who “doesn’t have a drinking problem” just got some uncomfortable reading material.

Called FTL1. In aging mice, higher levels of this protein weakened connections between brain cells and caused memory decline. Reducing it reversed some of that.

Mice aren’t humans. But every time something like this shows up, it’s one more piece of the puzzle of why the brain degrades. The idea that aging might be modifiable rather than fixed is no longer fringe science.

Filed under: things I hope pan out before I need them.

Oregon State. Captured the actual chemical interactions driving Alzheimer’s — copper ions triggering harmful protein behavior — as they happened.

Not a model. Not a simulation. Actual observation of the process.

Seeing something clearly is not the same as being able to stop it. But you can’t target what you can’t see. This is the kind of finding that makes treatment research more precise.

16-year study. ~800 people. Higher Vitamin D levels in midlife → lower tau protein levels later. Tau buildup is associated with Alzheimer’s and other forms of cognitive decline.

The implication is that the decisions you make in your 30s and 40s are already shaping what your brain looks like at 60 and 70.

Vitamin D is cheap. Sunlight is free. The study design isn’t perfect but it’s hard to argue against checking your levels.

New research confirms that bottled water contains significantly more microscopic plastic particles than earlier studies estimated. The discrepancy comes from improved detection methods — earlier analyses couldn’t identify the smallest nanoplastic particles, which turn out to be the most numerous.

How much more? The new counts run into the hundreds of thousands of particles per liter, depending on the brand and bottle type. Previous estimates were in the thousands.

The health implications remain contested. Research on what nanoplastics do inside the human body at these concentrations is ongoing, and there is no scientific consensus yet on the threshold at which harm becomes measurable. What is clear: the particles are there, they are abundant, and they are small enough to cross biological membranes.

Ozempic and Wegovy get talked about as weight loss drugs. That framing is increasingly inadequate for what GLP-1 receptor agonists appear to be doing.

The weight loss results are real and significant — patients losing 15 to 20% of body weight in clinical trials far exceeds what any previous pharmaceutical intervention achieved. But the downstream effects are where the story gets more interesting. Large-scale trials have shown meaningful reductions in cardiovascular events — heart attacks and strokes — in patients taking semaglutide, independent of weight loss effects. Separate research is showing promising signals in addiction behavior: patients reporting reduced cravings not just for food but for alcohol, nicotine, and other substances.